Format

Send to

Choose Destination
Gynecol Obstet Invest. 2019;84(1):99-106. doi: 10.1159/000491697. Epub 2018 Aug 22.

A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients.

Author information

1
Centre for Human Reproduction, Genesis Athens Clinic, Athens, Greece.
2
Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greecemarasimopoulou@hotmail.com.
3
Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Abstract

Poor responders are described as those In Vitro Fertilization (IVF) patients who are failing to respond to controlled ovarian stimulation protocols. Extensive research has focused on crafting the optimal treatment. However, it appears that each approach fails to be established as effective or guaranteed towards successful management. Platelet-Rich Plasma (PRP) is a novel, highly promising approach that has been successfully applied for an array of medical issues. In this case series, we present 3 poor responder patients with the common denominator of: failed IVF attempts, poor oocyte yield, and poor embryo quality. The option of oocyte donation was rejected. All patients were treated with autologous PRP ovarian infusion following written consent. Within a 3-month interval, follicle-stimulating hormone decreased by 67.33%, while Anti-Müllerian hormone increased by 75.18%. These impressive results on the biochemical infertility markers alone are classified as a complete biological paradox, coupled by improved embryo quality. Results report a natural conception at 24 weeks, an uncomplicated healthy pregnancy at 17 weeks and a successful live birth. To our knowledge, this is the first time such an approach and results are reported, where PRP treatment on poor responders lead to overcoming their challenging reproductive barrier.

KEYWORDS:

Improving follicle-stimulating hormone/anti-Müllerian hormone levels; Improving ovarian functionality; Platelet-rich plasma ovarian infusion; Poor responders

PMID:
30134239
DOI:
10.1159/000491697

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center